New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
Commonly Used Pressure Measure for Volume Assessment Discordant with Direct Measurement by BVA
Oak Ridge -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, today announces new data validating the benefits of the Company’s BVA-100 diagnostic in optimizing individualized therapy for heart failure patients. Data were presented at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure. The conference was held March 20-22, 2023 in Boston, Mass.
The study, titled “Persistent Pressure-Volume Dissociation During CardioMEMS Monitoring,” compared volume and pressure in heart failure (HF) patients who underwent CardioMEMS implantation to measure pressure, and direct measurement of total blood volume using Daxor’s blood volume analysis (BVA) diagnostic. Veraprapas Kittipibul M.D., lead investigator of the study concluded, “Less than half of patients had concordant pressure-volume changes during CardioMEMS monitoring. Universal volume-directed interventions (i.e. diuretics) in HF patients with high pressures might not be appropriate and should be discouraged.”
“Clinicians often rely on pressure monitoring alone to guide HF management by utilizing pressure measures as surrogates of volume status. This study confirms the significant body of evidence that pressure measurements are not adequate substitutes for direct measurements of circulating volume and that both metrics add valuable but different clinical data for the management of patients. Our BVA test informs clinicians with precise information to help manage and treat volume derangements in complex HF patients, enabling substantial improvements in mortality reduction, hospital readmission, hospital length of stay, and costs as demonstrated in previous studies,” said Michael Feldschuh, CEO and President of Daxor Corporation.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all.
Customer comments
No comments were found for New Study Confirms Daxor’s BVA-100 Volume Metric Compared to CardioMEMS Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients. Be the first to comment!